Zymeworks Pulls Plug On Early-Stage Cancer Potential As Therapy Unlikely To Provide Benefit
1. Zymeworks discontinues clinical development of ZW171 T-cell engager for cancer. 2. Decision based on poor benefit-risk profile from Phase 1 trial data. 3. Ongoing Phase 1 trial participants will continue treatment per investigator's discretion. 4. Company prioritizes resources on ZW251 and other products in pipeline. 5. ZYME stock dropped 5% to $14.07 following the news.